Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation

Rasmus Rivinius¹
Matthias Helmschrott¹
Arjang Ruhparwar²
Bastian Schmack²
Christian Erbel¹
Christian A Gleissner¹
Mohammadreza
Akhavanpoor¹
Lutz Frankenstein¹
Fabrice F Darche¹
Patrick A Schweizer¹
Dierk Thomas¹
Philipp Ehlermann¹
Tom Bruckner³
Hugo A Katus¹
Andreas O Doesch¹

¹Department of Cardiology, Angiology and Pneumology, ²Department of Cardiac Surgery, Heidelberg University Hospital, ³Institute for Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany

Correspondence: Andreas O Doesch
Medizinische Klinik, Universitätsklinikum Heidelberg, Innere Medizin III – Abteilung für Kardiologie, Angiologie und Pneumologie, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
Tel +49 6221 56 39936
Fax +49 6221 56 4105
Email andreas.doesch@med.uni-heidelberg.de

Background: Amiodarone is a frequently used antiarrhythmic drug in patients with end-stage heart failure. Given its long half-life, pre-transplant use of amiodarone has been controversially discussed, with divergent results regarding morbidity and mortality after heart transplantation (HTX).

Aim: The aim of this study was to investigate the effects of long-term use of amiodarone before HTX on early post-transplant atrial fibrillation (AF) and mortality after HTX.

Methods: Five hundred and thirty patients (age ≥ 18 years) receiving HTX between June 1989 and December 2012 were included in this retrospective single-center study. Patients with long-term use of amiodarone before HTX (≥ 1 year) were compared to those without long-term use (none or <1 year of amiodarone). Primary outcomes were early post-transplant AF and mortality after HTX. The Kaplan–Meier estimator using log-rank tests was applied for freedom from early post-transplant AF and survival.

Results: Of the 530 patients, 74 (14.0%) received long-term amiodarone therapy, with a mean duration of 32.3 ± 26.3 months. Mean daily dose was 223.0 ± 75.0 mg. Indications included AF, Wolff–Parkinson–White syndrome, ventricular tachycardia, and ventricular fibrillation. Patients with long-term use of amiodarone before HTX had significantly lower rates of early post-transplant AF ($P=0.0105$). Further, Kaplan–Meier analysis of freedom from early post-transplant AF showed significantly lower rates of AF in this group ($P=0.0123$). There was no statistically significant difference between patients with and without long-term use of amiodarone prior to HTX in 1-year ($P=0.8596$), 2-year ($P=0.8620$), 5-year ($P=0.2737$), or overall follow-up mortality after HTX ($P=0.1049$). Moreover, Kaplan–Meier survival analysis showed no statistically significant difference in overall survival ($P=0.1786$).

Conclusion: Long-term use of amiodarone in patients before HTX significantly reduces early post-transplant AF and is not associated with increased mortality after HTX.

Keywords: amiodarone, atrial fibrillation, heart failure, heart transplantation, mortality

Introduction

Life-threatening arrhythmias are the most common cause for sudden cardiac death and pose a great danger for patients with end-stage heart failure.¹ Antiarrhythmic treatment with amiodarone for atrial or ventricular arrhythmias is effective and is commonly used in clinical practice.^{2,3} Amiodarone has been demonstrated to maintain normal sinus rhythm in patients with atrial fibrillation (AF) and to decrease the rate of recurrence of ventricular tachycardia.^{2,3} Especially in patients on the waiting list for heart transplantation (HTX), it remains a preferred antiarrhythmic medication as it can be used

in patients with end-stage heart failure and severely reduced left ventricular ejection fraction for the management of persistent arrhythmias.^{4,5}

Since it is a highly lipophilic drug, amiodarone is extensively distributed into the body's tissues with a reported half-life ranging from 60 days in patients receiving short-term therapy up to 120 days in patients with long-term use of amiodarone.^{6–8} This raises the question whether the use of amiodarone before HTX may be associated with increased morbidity and mortality after HTX as the newly transplanted heart is exposed to this drug. On the other hand, the long half-life of amiodarone could be a potential safeguard against arrhythmias in the early post-transplant period.

Hence, the aim of this large retrospective single-center study was to investigate the effects of long-term use of amiodarone before HTX on early post-transplant AF and mortality after HTX.

Methods

Patients

This study was reviewed and approved by the ethics committee of the University of Heidelberg, Heidelberg, Germany, and was conducted in accordance with the ethical standards of the 2013 Declaration of Helsinki. All adult patients (≥ 18 years) receiving HTX at the Heidelberg Heart Center, Heidelberg, Germany, between June 1989 and December 2012 were included in this study. Patients with repeated cardiac transplantation were excluded. Data were retrieved from the Heidelberg Registry for Heart Transplantation. Written informed consent was obtained for the Heidelberg HTX register. Patients were divided into two groups based on their treatment with amiodarone before HTX: patients with at least 1 year of pre-transplant use of amiodarone immediately before HTX were included in the “long-term use of amiodarone” group, whereas patients with no or less than 1 year of pre-transplant use of amiodarone prior to HTX were included in the “no long-term use of amiodarone” group. Moreover, duration (in months) and daily dose (in milligrams) of pre-transplant long-term use of amiodarone were reviewed and evaluated. Primary outcomes were early post-transplant AF (AF ≤ 30 days after HTX) lasting 30 seconds or longer and mortality after HTX.

Follow-up

All available records pertaining to heart rhythm in the early post-transplant period (≤ 30 days after HTX) were assessed. During the initial hospital stay, patients were monitored using continuous telemetry. Additionally, 12-lead electrocardiography (ECG) was performed on a regular basis

and in case of any noted arrhythmia on telemetry. Also, 24-hour Holter recording was performed to detect arrhythmic disorders.

After the initial hospital stay, patients were seen on a monthly basis during the first 6 months after HTX, then bimonthly until the end of the first year, and thereafter three times per year (or if clinically indicated).^{9,10} Routine follow-up included medical history taking, physical examination, 12-lead ECG, and routine laboratory analysis (including immunosuppressive drug monitoring). Further, according to center standard, echocardiography and endomyocardial biopsy were performed.^{11,12}

Post-transplant medication

Post-transplant medication including immunosuppressive drug therapy was applied according to center standard. Immunosuppressive drug target levels were routinely monitored by laboratory analysis. The initial immunosuppressive regimen of cyclosporine A (CsA) and azathioprine (AZA) was subsequently replaced by CsA and mycophenolate mofetil (MMF) from 2001 onward, and by tacrolimus (TAC) and MMF from 2006 onward. Simultaneously, steroids (prednisolone) were also administered.^{9,10}

Statistical analysis

Statistical analysis was performed with SAS (Version 9.3, SAS Institute, Cary, NC, USA). Data were expressed as mean $\pm$ standard deviation (SD) or as absolute number (n) with percentage (%). Student's *t*-test was used for continuous variables and chi-squared test for categorical variables. The Kaplan–Meier estimator using log-rank tests was applied for freedom from early post-transplant AF and for survival after HTX.

Analysis of maximum-likelihood estimation was applied to evaluate a possible association between time of pre-transplant use of amiodarone and survival of patients after HTX. Time of pre-transplant long-term use of amiodarone (in months) was used as the analysis variable and survival of patients after HTX (in months) as the dependent variable. A *P*-value of <0.05 was considered to be statistically significant.

Demographic data included recipient age, sex, body mass index (BMI), coronary artery disease (CAD), arterial hypertension, dyslipidemia, diabetes mellitus, and renal insufficiency. Donor data included age, sex, and BMI. Principal diagnoses for HTX were categorized as nonischemic cardiomyopathy (CMP), ischemic CMP, valvular heart disease, and cardiac amyloidosis. Further, transplant sex

mismatch and the perioperative data (type of anastomosis [biatrial, bicaval, or total orthotopic HTX] and ischemic time) were analyzed.

Results

Patient characteristics

Five hundred and thirty patients (age ≥ 18 years) receiving HTX at the Heidelberg Heart Center between June 1989 and December 2012 were included in this study. Among these, 74 patients received long-term therapy with amiodarone, whereas 456 patients did not receive long-term therapy with amiodarone.

In patients receiving long-term therapy with amiodarone, mean recipient age at HTX was 53.1 ± 8.1 years, and the mean follow-up period after HTX was 7.2 ± 6.5 years, with 59 patients being male (79.7%). Mean donor age was 40.4 ± 13.2 years, with 30 donors being male (40.5%).

In the other group, mean recipient age at HTX was 51.5 ± 10.8 years, and mean follow-up period after HTX was 6.8 ± 6.1 years, with 353 patients being male (77.4%). Mean donor age was 39.5 ± 13.3 years, with 207 donors being male (45.4%).

With regard to BMI, no statistically significant differences between the recipient ($P=0.0854$) and donor groups ($P=0.8131$) were detected. Comorbidities at the time of HTX, including CAD ($P=0.6108$), arterial hypertension ($P=0.6527$), dyslipidemia ($P=0.1390$), and diabetes mellitus ($P=0.8765$), were not statistically significantly different except for renal insufficiency. Patients with long-term use of amiodarone had a significantly higher rate of renal insufficiency (52 of 74 [70.3% of subgroup] vs 253 of 456 [55.5% of subgroup], $P=0.0170$).

Considering the principal diagnoses for HTX, significantly more patients with nonischemic CMP were observed in the long-term use of amiodarone group (48 of 74 [64.9%] vs 236 of 456 [51.7%], $P=0.0359$), whereas significantly more patients with valvular heart disease (29 of 456 [6.4%] vs 0 of 74 [0.0%], $P=0.0257$) and cardiac amyloidosis (36 of 456 [7.9%] vs 0 of 74 [0.0%], $P=0.0123$) were observed in the opposite group. No statistically significant difference was observed for ischemic CMP as the principal diagnosis for HTX (26 of 74 [35.1%] vs 155 of 456 [34.0%], $P=0.8474$). Furthermore, there was no statistically significant difference between the two groups with regard to the transplant sex mismatch (37 of 74 [50.0% of subgroup] vs 192 of 456 [42.1% of subgroup], $P=0.2035$).

Perioperative data including anastomosis type, with further subgroups of biatrial HTX ($P=0.6786$), bicaval HTX

($P=0.1242$), and total orthotopic HTX ($P=0.3751$), as well as ischemic time ($P=0.5763$) showed no statistically significant difference between the groups. Patient characteristics are presented in Table 1.

Duration, daily dose, and indications for long-term use of amiodarone

The mean duration of long-term therapy of amiodarone before HTX was 32.3 ± 26.3 months, ranging from 12 to 168 months. The mean daily amiodarone dose was 223.0 ± 75.0 mg, ranging from 100 to 400 mg per day. Indications for long-term therapy with amiodarone were AF in ten patients (13.5% of subgroup), Wolff–Parkinson–White syndrome in one patient (1.4% of subgroup), ventricular tachycardia in 57 patients (77.0% of subgroup), and ventricular fibrillation in six patients (8.1% of subgroup). Indications for pre-transplant use of amiodarone are displayed in Figure 1.

Initial post-transplant medication

Comparison of the initial immunosuppressive drug therapy showed no statistically significant differences between patients with or without long-term use of amiodarone before HTX with regard to the use of CsA ($P=0.2426$) or TAC ($P=0.2426$). Neither the administration of AZA ($P=0.7485$) nor the use of MMF ($P=0.7485$) showed a statistically significant difference. Moreover, there were no statistically significant differences regarding the use of acetylsalicylic acid ($P=0.5496$), angiotensin-converting-enzyme inhibitor/sartan ($P=0.2562$), or statin ($P=0.7005$). In addition, neither the administration of beta-blocker ($P=0.1561$) nor the use of calcium channel blocker ($P=0.3792$) showed a statistically significant difference. Medication used within 30 days after HTX are given in Table 2.

Early post-transplant AF

Sixty-one of the 530 HTX patients (11.5%) developed AF in the early post-transplant period. The chi-squared test was applied to determine whether there was a significant difference in the occurrence of early post-transplant AF (AF ≤ 30 days after HTX) between patients with and without long-term use of amiodarone before HTX by comparing the corresponding expected and observed frequencies.

In patients with long-term amiodarone use prior to HTX, the expected frequencies predicted 8.5 patients with AF after HTX (8.5 of 74 [11.5% of all patients with long-term amiodarone use], 8.5 of 61 [14.0% of patients with AF], and 8.5 of 530 [1.6% of all patients]). In the other group, the expected frequencies predicted 52.5 patients with AF after

Table 1 Patient characteristics

Parameter	Long-term use of amiodarone prior to HTX (n=74)	No long-term use of amiodarone prior to HTX (n=456)	P-value
Recipient data			
Age in years, mean $\pm$ SD	53.1 $\pm$ 8.1	51.5 $\pm$ 10.8	0.1536
Male sex, n (%)	59 (79.7)	353 (77.4)	0.6567
BMI, mean $\pm$ SD	25.4 $\pm$ 3.4	24.7 $\pm$ 3.9	0.0854
CAD, n (%)	33 (44.6)	189 (41.4)	0.6108
Arterial hypertension, n (%)	42 (56.8)	246 (53.9)	0.6527
Dyslipidemia, n (%)	53 (71.6)	286 (62.7)	0.1390
Diabetes mellitus, n (%)	26 (35.1)	156 (34.2)	0.8765
Renal insufficiency, n (%)	52 (70.3)	253 (55.5)	0.0170*
Donor data			
Age in years, mean $\pm$ SD	40.4 $\pm$ 13.2	39.5 $\pm$ 13.3	0.6090
Male sex, n (%)	30 (40.5)	207 (45.4)	0.4360
BMI, mean $\pm$ SD	24.7 $\pm$ 3.8	24.5 $\pm$ 4.0	0.8131
Principal diagnosis for HTX			
Nonischemic CMP, n (%)	48 (64.9)	236 (51.7)	0.0359*
Ischemic CMP, n (%)	26 (35.1)	155 (34.0)	0.8474
Valvular heart disease, n (%)	0 (0.0)	29 (6.4)	0.0257*
Cardiac amyloidosis, n (%)	0 (0.0)	36 (7.9)	0.0123*
Transplant sex mismatch			
Mismatch, n (%)	37 (50.0)	192 (42.1)	0.2035
Donor (m) to recipient (f), n (%)	4 (5.4)	23 (5.0)	0.8956
Donor (f) to recipient (m), n (%)	33 (44.6)	169 (37.1)	0.2158
Perioperative data			
Biatial HTX, n (%)	24 (32.4)	137 (30.0)	0.6786
Bicaval HTX, n (%)	11 (14.9)	104 (22.8)	0.1242
Total orthotopic HTX, n (%)	39 (52.7)	215 (47.2)	0.3751
Ischemic time, min, mean $\pm$ SD	207.4 $\pm$ 67.5	212.1 $\pm$ 64.9	0.5763

Note: *Statistically significant ($P < 0.05$).

Abbreviations: HTX, heart transplantation; BMI, body mass index; CAD, coronary artery disease; CMP, cardiomyopathy; m, male; f, female; min, minutes; n, number; SD, standard deviation.

HTX (52.5 of 456 [11.5% of all patients without long-term amiodarone use], 52.5 of 61 [86.0% of patients with AF], and 52.5 of 530 [9.9% of all patients]).

In contrast to these results, the observed frequencies differed significantly ($P=0.0105$), showing that patients with

long-term use of amiodarone prior to HTX had lower rates of early post-transplant AF, with only two patients with AF after HTX (2 of 74 [2.7% of all patients with long-term use of amiodarone], 2 of 61 [3.3% of patients with AF], and 2 of 530 [0.4% of all patients]).

Figure 1 Indications for pre-transplant use of amiodarone.

Notes: Indications for long-term amiodarone therapy were atrial fibrillation in ten patients (13.5%), Wolff-Parkinson-White syndrome in one patient (1.4%), ventricular tachycardia in 57 patients (77.0%), and ventricular fibrillation in six patients (8.1%).

Table 2 Initial post-transplant medication

Parameter	Long-term use of amiodarone prior to HTX (n=74)	No long-term use of amiodarone prior to HTX (n=456)	P-value
Cyclosporine A, n (%)	43 (58.1)	297 (65.1)	0.2426
Tacrolimus, n (%)	31 (41.9)	159 (34.9)	0.2426
Azathioprine, n (%)	36 (48.6)	231 (50.7)	0.7485
Mycophenolate mofetil, n (%)	38 (51.4)	225 (49.3)	0.7485
Steroids, n (%)	74 (100.0)	456 (100.0)	na
Acetylsalicylic acid, n (%)	7 (9.5)	34 (7.5)	0.5496
Beta-blocker, n (%)	7 (9.5)	72 (15.8)	0.1561
Ivabradine, n (%)	3 (4.1)	27 (5.9)	0.5191
Calcium channel blocker, n (%)	15 (20.3)	114 (25.0)	0.3792
Dihydropyridine, n (%)	4 (5.4)	47 (10.3)	0.1848
Non-dihydropyridine, n (%)	11 (14.9)	67 (14.7)	0.9691
ACE inhibitor/sartan, n (%)	29 (39.2)	211 (46.3)	0.2562
Diuretic, n (%)	74 (100.0)	456 (100.0)	na
Statin, n (%)	28 (37.8)	162 (35.5)	0.7005
Gastric protection, n (%) (PPI/H ₂ blocker)	74 (100.0)	456 (100.0)	na

Abbreviations: HTX, heart transplantation; ACE inhibitor, angiotensin-converting-enzyme inhibitor; PPI, proton pump inhibitor; H₂ blocker, histamine receptor blocker; n, number; na, not applicable.

Consequently, patients without long-term use of amiodarone prior to HTX had higher rates of early post-transplant AF, including 59 patients with AF after HTX (59 of 456 [12.9% of all patients without long-term use of amiodarone], 59 of 61 [96.7% of patients with AF], and 59 of 530 [11.1% of all patients]). The influence of long-term use of amiodarone on post-transplant AF is shown in Table 3.

Further, Kaplan–Meier analysis of freedom from early post-transplant AF showed significantly lower rates of AF in patients with long-term use of amiodarone before HTX (2 of 61 [3.3% of subgroup] vs 59 of 61 [96.7% of subgroup], $P=0.0123$). The Kaplan–Meier estimator (freedom from early post-transplant AF) is given in Figure 2.

Post-transplant mortality

Of the 530 HTX patients, 254 (47.9%) died during the overall follow-up. There was no statistically significant difference between the patients with and without long-term use of amiodarone prior to HTX in 1-year follow-up mortality (amiodarone: 16 of 71 patients [22.5% of subgroup] vs no amiodarone: 97 of 449 patients [21.6% of subgroup], $P=0.8596$), 2-year follow-up mortality (amiodarone: 17 of 69 patients [24.6% of subgroup] vs no amiodarone: 114 of 445 patients [25.6% of subgroup], $P=0.8620$), 5-year follow-up mortality (amiodarone: 18 of 60 patients [30.0% of subgroup] vs no amiodarone: 144 of 386 patients [37.3% of subgroup], $P=0.2737$), or overall follow-up mortality (amiodarone: 29 of 74 patients [39.2% of subgroup] vs no amiodarone: 225 of 456 patients [49.3% of subgroup], $P=0.1049$). The influence of long-term use of amiodarone on post-transplant mortality is shown in Table 4.

In addition, the Kaplan–Meier survival analysis showed no statistically significant difference in the overall survival between patients with and without long-term use of amiodarone prior to HTX ($P=0.1786$). The Kaplan–Meier estimator (overall follow-up survival) is given in Figure 3. Moreover, analysis of maximum-likelihood estimation showed no evidence in this study for an association between time of pre-transplant long-term use of amiodarone (ranging from 12 to 168 months) and survival of patients after HTX (hazard ratio [HR] =1.000; 95% HR confidence interval [CI]: 0.983–1.017; $P=0.9765$).

Discussion

Background

The use of amiodarone in patients with end-stage heart failure and arrhythmias prior to HTX has been controversially discussed.^{4,5,13–18} Due to its lipophilic character, large volume of distribution, reduced clearance rate, and long half-life, the redistribution of amiodarone from the recipient's tissues to the transplanted donor's heart has been reported.^{6–8,19} This exposure of the newly transplanted heart to amiodarone may have an influence on post-transplant arrhythmias and mortality after HTX. Therefore, the purpose of this study was to investigate the effects of long-term use of amiodarone before HTX on early post-transplant AF and mortality after HTX.

Patient characteristics

Analysis of recipient data between patients with and without pre-transplant long-term amiodarone therapy showed

Table 3 Influence of long-term use of amiodarone on early post-transplant atrial fibrillation

	Long-term use of amiodarone prior to HTX	No long-term use of amiodarone prior to HTX	Total
Expected frequencies			
AF after HTX	8.5	52.5	61
Total percentage	8.5 of 530 (1.6%)	52.5 of 530 (9.9%)	61 of 530 (11.5%)
Row percentage	8.5 of 61 (14.0%)	52.5 of 61 (86.0%)	61 of 61 (100.0%)
Column percentage	8.5 of 74 (11.5%)	52.5 of 456 (11.5%)	61 of 530 (11.5%)
No AF after HTX	65.5	403.5	469
Total percentage	65.5 of 530 (12.4%)	403.5 of 530 (76.1%)	469 of 530 (88.5%)
Row percentage	65.5 of 469 (14.0%)	403.5 of 469 (86.0%)	469 of 469 (100.0%)
Column percentage	65.5 of 74 (88.5%)	403.5 of 456 (88.5%)	469 of 530 (88.5%)
Total	74	456	530
Total percentage	74 of 530 (14.0%)	456 of 530 (86.0%)	530 of 530 (100.0%)
Row percentage	74 of 530 (14.0%)	456 of 530 (86.0%)	530 of 530 (100.0%)
Column percentage	74 of 74 (100.0%)	456 of 456 (100.0%)	530 of 530 (100.0%)
<i>P=1.0000</i>			
Observed frequencies			
AF after HTX	2	59	61
Total percentage	2 of 530 (0.4%)	59 of 530 (11.1%)	61 of 530 (11.5%)
Row percentage	2 of 61 (3.3%)	59 of 61 (96.7%)	61 of 61 (100.0%)
Column percentage	2 of 74 (2.7%)	59 of 456 (12.9%)	61 of 530 (11.5%)
No AF after HTX	72	397	469
Total percentage	72 of 530 (13.6%)	397 of 530 (74.9%)	469 of 530 (88.5%)
Row percentage	72 of 469 (15.4%)	397 of 469 (84.6%)	469 of 469 (100.0%)
Column percentage	72 of 74 (97.3%)	397 of 456 (87.1%)	469 of 530 (88.5%)
Total	74	456	530
Total percentage	74 of 530 (14.0%)	456 of 530 (86.0%)	530 of 530 (100.0%)
Row percentage	74 of 530 (14.0%)	456 of 530 (86.0%)	530 of 530 (100.0%)
Column percentage	74 of 74 (100.0%)	456 of 456 (100.0%)	530 of 530 (100.0%)
<i>P=0.0105*</i>			

Note: *Statistically significant ($P<0.05$).

Abbreviations: HTX, heart transplantation; AF, atrial fibrillation.

no statistically significant differences with regard to age, male sex, BMI, CAD, arterial hypertension, dyslipidemia, or diabetes mellitus. Donor age, sex, BMI, and transplant sex mismatch did not vary significantly between the groups. Furthermore, type of anastomosis (biatrial, bicaval, or total

orthotopic HTX) and ischemic time were not statistically different.

Patients with long-term use of amiodarone had a significantly higher rate of renal insufficiency, although amiodarone is cleared predominantly via hepatic metabolism and $<1\%$ is excreted via urine.^{6,8} However, rhabdomyolysis – which can lead to kidney failure and death – may occur in patients treated simultaneously with amiodarone and simvastatin, especially in doses greater than 20 mg per day.²⁰ Additionally, renal dysfunction has been considered a risk factor for death after HTX.²¹

With regard to principal diagnoses for HTX, groups differed slightly as more patients with nonischemic CMP were found in the long-term use of amiodarone group, while more patients with valvular heart disease and cardiac amyloidosis were found in the opposite group. However, no difference between groups was found in patients with ischemic CMP as the principal diagnosis for HTX.

Therefore, the comparison of patients with and without long-term amiodarone use indicated no major differences in demographic data, providing two similar groups principally varying only in terms of prior amiodarone therapy.

Figure 2 Kaplan–Meier estimator (freedom from early post-transplant atrial fibrillation).

Note: Freedom from early post-transplant atrial fibrillation (≤ 30 days after HTX) in patients with/without pre-transplant use of amiodarone.

Abbreviations: HTX, heart transplantation; AF, atrial fibrillation.

Table 4 Influence of long-term use of amiodarone on mortality after HTX

Parameter	Long-term use of amiodarone prior to HTX (n=74)	No long-term use of amiodarone prior to HTX (n=456)	P-value
1-year follow-up mortality	16 of 71 (22.5%)	97 of 449 (21.6%)	0.8596
2-year follow-up mortality	17 of 69 (24.6%)	114 of 445 (25.6%)	0.8620
5-year follow-up mortality	18 of 60 (30.0%)	144 of 386 (37.3%)	0.2737
Overall follow-up mortality	29 of 74 (39.2%)	225 of 456 (49.3%)	0.1049

Abbreviations: HTX, heart transplantation; n, number.

Duration, daily dose, and indications for long-term use of amiodarone

Former studies have reported a wide spectrum of duration of pre-transplant amiodarone therapy ranging from <1 week to a minimum duration of 3 months.^{5,16} A longer duration of pre-transplant amiodarone therapy has been associated with an elevated post-transplant mortality.⁵ Accordingly, we focused on long-term-use of amiodarone before HTX with a minimum use of 12 months to minimize bias regarding duration of intake and achievement of steady state due to the long half-life of amiodarone ranging up to 120 days.⁸

Increased mortality with amiodarone use may not only be associated with the duration of intake but also with the amount of daily dose. In this study, the mean daily dose was 223.0±75.0 mg, which is comparable to Macdonald et al¹³ reporting a mean daily dose of 247.0±31.0 mg without an elevated post-transplant mortality in patients with previous amiodarone therapy. In contrast, Chin et al⁵ described a mean daily dose of 327.0±130.0 mg with an increased post-transplant mortality in patients with pre-transplant use of amiodarone for more than 4 weeks.

Amiodarone has been used for the treatment of supraventricular and ventricular arrhythmias.^{2,3} Indications for

pre-transplant long-term therapy with amiodarone in this study were AF (13.5%), Wolff–Parkinson–White syndrome (1.4%), ventricular tachycardia (77.0%), and ventricular fibrillation (8.1%).

Initial post-transplant medication

Atrial tachyarrhythmias after HTX have been associated with acute rejection episodes.²² As rejection episodes are influenced by immunosuppressive drug therapy,¹² we compared the initial immunosuppressive regimen within 30 days after HTX of patients with and without long-term use of amiodarone prior to HTX. We found no statistically significant differences (CsA, TAC, AZA, or MMF, all *P*-values were not significant).

Antiarrhythmic drugs other than amiodarone (beta-blockers or calcium channel blockers) can influence the occurrence or frequency of AF.³ To reveal the effects of concomitantly administered antiarrhythmic drugs, we compared the initial post-transplant medication within 30 days after HTX of patients with and without long-term use of amiodarone before HTX. The use of beta-blocker, ivabradine, or calcium channel blocker did not differ significantly between the groups (all *P*-values were not significant), minimizing the potential bias with regard to antiarrhythmic drugs.

Early post-transplant AF

Pre-transplant amiodarone therapy has been associated with post-transplant sinus bradycardia as a result of its negative chronotropic effects through calcium channel inhibition and beta-receptor blockade, requiring temporary or permanent pacing support in some patients.^{4,23,24} In contrast, however, its potential as a safeguard against tachyarrhythmias in the early post-transplant period – due to the long half-life of pre-transplant use of amiodarone – has been poorly studied.

AF in the early post-transplant period after HTX has a reported incidence of 7.9%–18.2%.^{25,26} In this study, 61 of 530 patients (11.5% of total) developed AF in the early post-transplant period. Patients with AF are at an increased risk of morbidity and mortality as a result of thromboembolic complications such as stroke.²⁷ Moreover, several studies have shown an increased mortality in patients with AF after

Figure 3 Kaplan–Meier estimator (overall follow-up survival).

Note: Survival of patients with/without pre-transplant use of amiodarone.

Abbreviation: HTX, heart transplantation.

HTX compared to patients with sinus rhythm.^{25,26,28} In order to investigate the influence of long-term use of amiodarone on post-transplant AF between patients with and without long-term amiodarone use prior to HTX, the expected and observed frequencies of AF of both groups were compared. Here, patients with long-term use of amiodarone before HTX had significantly lower rates of early post-transplant AF ($P=0.0105$). Additionally, Kaplan–Meier analysis of freedom from early post-transplant AF showed significantly lower rates of AF in patients with long-term use of amiodarone before HTX compared to those without ($P=0.0123$).

Post-transplant mortality

With regard to post-transplant mortality, the scientific community is divided, as some studies reported increased post-transplant mortality in patients with amiodarone use before HTX,^{15,16} whereas other studies showed no difference.^{13,14,17} Macdonald et al¹³ compared post-transplant mortality between 19 patients with pre-transplant amiodarone therapy (mean duration of therapy: 9.0 ± 2.2 months; mean daily dose: 247.0 ± 31.0 mg) and 31 patients as control. They found no statistically significant differences of prior amiodarone therapy on early allograft inotropic function or on clinical outcomes such as length of hospital stay or mortality within the first month after HTX (mortality was 5.3% and 9.7% in patients with and without amiodarone use, respectively).¹³

Similar results regarding morbidity and mortality were reported by Chelimsky-Fallick et al.¹⁴ They retrospectively matched 29 amiodarone patients (mean duration of therapy: 11.0 ± 22.0 months; mean daily dose: 360.0 ± 230.0 mg) with 29 control patients. The 30-day mortality did not differ significantly as two patients in the amiodarone group (6.9%) and one patient in the control group (3.4%) died.¹⁴ In contrast, Konertz et al¹⁵ reported a higher rate of complications after HTX in patients with pre-transplant use of amiodarone, which included mortality, difficult weaning from extracorporeal circulation, elevated inotropic doses, and prolongation of respiratory support. Two of six patients (33.3%) with pre-transplant amiodarone therapy died compared to three of 26 patients (11.5%) without prior use of amiodarone. The duration of amiodarone therapy or mean daily dose were not reported.¹⁵

The three aforementioned studies were of rather small sample size and covered only a short follow-up period after HTX (mean follow-up <1 year). Further, they did not focus on differences in duration of pre-transplant amiodarone therapy. This approach was pursued by Chin et al,⁵ who split 106 patients into groups based on their pre-transplant

use of amiodarone: <1 week (one patient, mean dose of 300 mg), 1–4 weeks (five patients, mean dose of 928 ± 492 mg), and >4 weeks (32 patients, mean dose of 327 ± 130 mg). Five patients (no mean dose of amiodarone provided) received amiodarone for an unspecific period, and 63 patients had no prior amiodarone therapy. There was a threefold increase of in-hospital mortality in patients treated with amiodarone for more than 4 weeks (ten of 32 [31.3%]) in comparison to patients without amiodarone (six of 63 [9.5%]), indicating that a longer pre-transplant use of amiodarone may be associated with increased mortality.⁵ Likewise, in the aforementioned studies, sample size was small and follow-up covered only a short period after HTX, although focusing on duration of pre-transplant use of amiodarone.

Considering former studies with short-term follow-ups, Blomberg et al¹⁶ conducted a study with 20 patients receiving amiodarone for a minimum of 3 months before HTX, and 65 HTX-patients without prior amiodarone therapy served as control. They provided a 5-year survival analysis. Here, eleven of 20 patients in the amiodarone group (55.0%) and 15 of 65 in the other group (23.1%) died.¹⁶ Interestingly, one-third of deaths in the amiodarone group occurred between 30 and 60 days after HTX, leaving room for speculations that a longer follow-up in the former studies might have had an impact on mortality assessment.^{13,14}

A more recent large retrospective study with a total of 396 patients by Sanchez-Lazaro et al¹⁷ observed no significant differences in acute graft failure or early mortality. They examined 25 patients with a minimum use of amiodarone for at least 30 days before transplantation and 371 patients without pre-transplant use of amiodarone. Three of 25 patients (12.0%) with pre-transplant amiodarone therapy died versus 39 of 371 patients (10.5%) without prior use of amiodarone. The mean daily dose of amiodarone was not reported.¹⁷

The latest contribution to this issue was presented by Yerebakan et al¹⁸ at the 34th Annual Meeting of the International Society for Heart and Lung Transplantation in San Diego, California, USA, in April 2014. The authors used a propensity score to match 86 patients with pre-transplant use of amiodarone to 86 controls. There was a significantly increased in-hospital mortality after HTX in patients receiving prior treatment with amiodarone (7.0% vs 0.0%, $P=0.01$). However, long-term survival after HTX was similar between groups ($P=0.72$). As the final data set has not been published yet, preliminary results should be interpreted cautiously.¹⁸

Study limitations

Our findings were derived from a single-center study with 530 patients including 74 patients with long-term therapy of amiodarone before HTX. Therefore, sufficient power to compare results with multi-center studies was provided. Moreover, in contrast to multicenter studies, patients received a comparable center-specific induction regimen and follow-up, thus minimizing potential confounders. Second, the retrospective nature of this analysis carries the limitations of such a study design.^{9,10} Third, a possible era effect cannot be ruled out, given the long follow-up period.^{11,12}

Conclusion

The use of amiodarone in patients with end-stage heart failure and arrhythmias before HTX has been controversially discussed.^{4,5,13–18} This large retrospective single-center study with 530 patients aimed to investigate the effects of long-term use of amiodarone before HTX on early post-transplant AF and mortality after HTX.

Notably, patients with long-term use of amiodarone before HTX had significantly lower rates of early post-transplant AF ($P=0.0105$). In addition, Kaplan–Meier analysis of freedom from early post-transplant AF showed significantly lower rates of AF in this group ($P=0.0123$). Moreover, we found no evidence of increased post-transplant mortality in patients with pre-transplant long-term use of amiodarone with regard to 1-year ($P=0.8596$), 2-year ($P=0.8620$), 5-year ($P=0.2737$), or overall follow-up mortality after HTX ($P=0.1049$). Further, Kaplan–Meier survival analysis showed no statistically significant difference in the overall survival ($P=0.1786$).

Therefore, based on our results and the efficacy of amiodarone in the treatment of atrial and ventricular arrhythmias in patients with end-stage heart failure, we consider amiodarone an important antiarrhythmic drug in patients with severe heart failure awaiting HTX. Nevertheless, each indication for amiodarone has to be carefully taken into consideration for balancing its benefits and disadvantages. In addition, further large prospective randomized controlled studies are required to assess the effects of pre-transplant use of amiodarone on post-transplant outcomes.

Acknowledgment

The authors thank Gerda Baumann, Viola Deneke, and Berthold Klein for their assistance and advice.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Saravanan P, Davidson NC. Risk assessment for sudden cardiac death in dialysis patients. *Circ Arrhythm Electrophysiol*. 2010;3(5):553–559.
2. Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. *Heart Rhythm*. 2014;11(10):166–196.
3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2014;64(21):1–76.
4. Jennings DL, Martinez B, Montalvo S, Lanfear DE. Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients. *Heart Fail Rev*. 2015;20(5):573–578.
5. Chin C, Feindel C, Cheng D. Duration of preoperative amiodarone treatment may be associated with postoperative hospital mortality in patients undergoing heart transplantation. *J Cardiothorac Vasc Anesth*. 1999;13(5):562–566.
6. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. *Clin Pharmacokinet*. 1984;9(2):136–156.
7. Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. *J Am Coll Cardiol*. 1984;3(4):1059–1071.
8. Somani P. Basic and clinical pharmacology of amiodarone: relationship of antiarrhythmic effects, dose and drug concentrations to intracellular inclusion bodies. *J Clin Pharmacol*. 1989;29(5):405–412.
9. Doesch AO, Müller S, Konstandin M, et al. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal. *Transplant Proc*. 2010;42(9):3694–3699.
10. Rivinius R, Helmschrott M, Ruhparwar A, et al. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy. *Drug Des Devel Ther*. 2014;9:93–102.
11. Helmschrott M, Beckendorf J, Akyol C, et al. Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen. *Drug Des Devel Ther*. 2014;8:1307–1314.
12. Helmschrott M, Rivinius R, Ruhparwar A, et al. Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation. *Drug Des Devel Ther*. 2015;9:1217–1224.
13. Macdonald P, Hackworthy R, Keogh A, Sivathanan C, Chang V, Spratt P. The effect of chronic amiodarone therapy before transplantation on early cardiac allograft function. *J Heart Lung Transplant*. 1991;10:743–749.
14. Chelmsky-Fallick C, Middlekauff HR, Stevenson WG, et al. Amiodarone therapy does not compromise subsequent heart transplantation. *J Am Coll Cardiol*. 1992;20(7):1556–1561.
15. Konertz W, Weyand M, Deiwick M, Scheld HH. Is pretransplant antiarrhythmic drug therapy a risk factor? *Transplant Proc*. 1992;24(6):2677–2678.
16. Blomberg PJ, Feingold AD, Denofrio D, et al. Comparison of survival and other complications after heart transplantation in patients taking amiodarone before surgery versus those not taking amiodarone. *Am J Cardiol*. 2004;93(3):379–381.
17. Sanchez-Lazaro JJ, Almenar L, Martinez-Dolz L, et al. Does amiodarone influence early mortality in heart transplantation? *Transplant Proc*. 2006;38(8):2537–2538.
18. Yerebakan H, Naka Y, Sorabella R, et al. Amiodarone treatment prior to heart transplantation is associated with acute graft dysfunction and early mortality: a propensity-matched comparison. *J Heart Lung Transplant*. 2014;33(4):S105.
19. Giardina EG, Schneider M, Barr ML. Myocardial amiodarone and desethylamiodarone concentrations in patients undergoing cardiac transplantation. *J Am Coll Cardiol*. 1990;16(4):943–947.
20. Karimi S, Hough A, Beckey C, Parra D. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. *J Manag Care Pharm*. 2010;16(7):472–481.

21. Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. *J Heart Lung Transplant*. 1993;12(4):549–562.
22. Scott CD, Dark JH, McComb JM. Arrhythmias after cardiac transplantation. *Am J Cardiol*. 1992;70(11):1061–1063.
23. Bertolet BD, Eagle DA, Conti JB, Mills RM, Belardinelli L. Bradycardia after heart transplantation: reversal with theophylline. *J Am Coll Cardiol*. 1996;28(2):396–399.
24. DiBiase A, Tse TM, Schnittger I, Wexler L, Stinson EB, Valentine HA. Frequency and mechanism of bradycardia in cardiac transplant recipients and need for pacemakers. *Am J Cardiol*. 1991;67(16):1385–1389.
25. Dasari TW, Pavlovic-Surjancev B, Patel N, et al. Incidence, risk factors, and clinical outcomes of atrial fibrillation and atrial flutter after heart transplantation. *Am J Cardiol*. 2010;106(5):737–741.
26. Pavri BB, O’Nunain SS, Newell JB, Ruskin JN, William G. Prevalence and prognostic significance of atrial arrhythmias after orthotopic cardiac transplantation. *J Am Coll Cardiol*. 1995;25(7):1673–1680.
27. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. *J Am Coll Cardiol*. 2007;50(22):2156–2161.
28. Ahmari SA, Bunch TJ, Chandra A, et al. Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter. *J Heart Lung Transplant*. 2006;25(1):53–60.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>

Dovepress

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.